SCHEMBL4440949

SCHEMBL4440949

Cc1ccc(COc2coc(OC(=O)O)cc2=O)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.64
CYP1A2 P05177 1/20 0.64
CYP2C19 P33261 1/20 0.64
RECQL P46063 1/20 0.64
RAB9A P51151 1/20 0.64
MAPT P10636 1/20 0.43
MAOB P27338 3/20 0.41
MAOA P21397 1/20 0.41
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
LDHA P00338 1/20 0.40
KDM5A P29375 1/20 0.40
KDM2B Q8NHM5 1/20 0.40
KDM4C Q9H3R0 1/20 0.40
KDM5B Q9UGL1 1/20 0.40
FFAR4 Q5NUL3 1/20 0.40
THRA P10827 1/20 0.40
THRB P10828 1/20 0.40
ALDH1A1 P00352 1/20 0.40
PARP10 Q53GL7 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3334602 0.84 NPC1 (0.67) NPC1CYP1A2CYP2C19RECQLRAB9A
SCHEMBL9010386 0.74 MEN1 (0.50) NPC1CYP1A2CYP2C19RECQLRAB9A
SCHEMBL4441907 0.73 THRA (0.43) NPC1CYP1A2CYP2C19RECQLRAB9A
SCHEMBL10328621 0.73 NPC1 (0.53) NPC1CYP1A2CYP2C19RECQLRAB9A
SCHEMBL4447954 0.72 THRA (0.40) NPC1CYP1A2CYP2C19RECQLRAB9A
SCHEMBL988885 0.72 NPC1 (0.55) NPC1CYP1A2CYP2C19RECQLRAB9A
SCHEMBL8160885 0.71 CYP2C19 (0.51) NPC1CYP1A2CYP2C19RECQLRAB9A
SCHEMBL10328547 0.71 NPC1 (0.51) NPC1CYP1A2CYP2C19RECQLRAB9A
SCHEMBL9356623 0.71 RAB9A (0.52) NPC1CYP1A2CYP2C19RECQLRAB9A
SCHEMBL10328616 0.71 RXRA (0.52) NPC1CYP1A2CYP2C19RECQLRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2120923-B1 USE OF SUBSTITUTED PYRANONE ACID DERIVATIVES FOR THE TREATMENT OF METABOLIC SYNDROME SANOFI SA (FR) 2012-07-18 EP disclosed
EP-2120923-A1 USE OF SUBSTITUTED PYRANONE ACID DERIVATIVES FOR THE TREATMENT OF METABOLIC SYNDROME Sanofi-Aventis (FR) 2009-11-25 EP disclosed
WO-2008086949-A1 USE OF SUBSTITUTED PYRANONE ACID DERIVATIVES FOR THE TREATMENT OF METABOLIC SYNDROME SANOFI-AVENTIS (FR) 2008-07-24 WO disclosed